O	0	1	[
O	1	7	Effect
O	8	10	of
B-intervention	11	23	preoperative
I-intervention	24	33	lymphatic
I-intervention	34	46	chemotherapy
O	47	49	on
O	50	53	Bcl
O	53	54	-
O	54	55	2
O	56	59	and
O	60	63	Bax
O	64	74	expression
O	75	77	in
O	78	86	axillary
O	87	97	metastasis
O	98	100	of
O	101	107	breast
O	108	114	cancer
O	114	115	]
O	115	116	.

O	117	119	To
O	120	127	observe
O	128	131	the
O	132	142	expression
O	143	145	of
O	146	149	Bcl
O	149	150	-
O	150	151	2
O	152	155	and
O	156	159	Bax
O	160	168	proteins
O	169	172	and
O	173	177	cell
O	178	187	apoptosis
O	188	195	induced
O	196	198	by
O	199	211	preoperative
O	212	221	lymphatic
O	222	234	chemotherapy
O	235	239	with
O	240	250	epirubicin
O	250	251	-
O	251	260	activated
O	261	267	carbon
O	268	278	suspension
O	279	280	(
O	280	283	Epi
O	283	284	-
O	284	286	CH
O	286	287	)
O	288	290	in
O	291	294	the
O	295	300	cells
O	301	303	of
O	304	312	axillary
O	313	323	metastatic
O	324	329	lymph
O	330	334	node
O	335	337	of
O	338	344	breast
O	345	351	cancer
O	352	355	and
O	356	367	investigate
O	368	371	the
O	372	381	mechanism
O	381	382	.

B-total-participants	383	388	Sixty
O	389	397	patients
O	398	402	with
B-eligibility	403	409	breast
I-eligibility	410	416	cancer
I-eligibility	417	419	of
I-eligibility	420	426	stages
I-eligibility	427	429	II
I-eligibility	429	430	-
I-eligibility	430	433	III
O	434	438	were
O	439	447	randomly
O	448	455	divided
O	456	460	into
O	461	464	two
O	465	471	groups
O	471	472	.

B-intervention-participants	473	478	Forty
O	479	487	patients
O	488	490	in
O	491	494	Epi
O	494	495	-
O	495	497	CH
O	498	503	group
O	504	508	were
O	509	517	injected
O	518	522	with
O	523	525	10
O	526	528	mg
O	529	532	Epi
O	532	533	-
O	533	535	CH
O	536	538	in
O	539	542	the
O	543	549	tissue
O	550	556	around
O	557	560	the
O	561	568	primary
O	569	574	tumor
O	575	577	or
O	578	584	biopsy
O	585	593	excision
O	594	596	72
O	597	598	h
O	599	605	before
O	606	615	operation
O	615	616	.

B-control-participants	617	623	Twenty
O	624	632	patients
O	633	635	in
O	636	639	the
B-control	640	647	control
O	648	653	group
O	654	658	were
O	659	667	injected
O	668	672	with
O	673	675	10
O	676	678	mg
O	679	689	epirubicin
O	690	698	solution
O	699	701	in
O	702	705	the
O	706	710	same
O	711	717	region
O	717	718	.

O	719	722	The
O	723	730	stained
O	731	736	lymph
O	737	742	nodes
O	743	747	full
O	748	750	of
O	751	756	tumor
O	757	762	cells
O	763	765	in
O	766	769	Epi
O	769	770	-
O	770	772	CH
O	773	778	group
O	779	782	and
O	783	786	the
O	787	790	non
O	790	791	-
O	791	798	stained
O	799	804	nodes
O	805	807	in
O	808	811	the
O	812	819	control
O	820	825	group
O	826	830	were
O	831	839	selected
O	840	843	for
O	844	853	apoptotic
O	854	863	detection
O	864	866	by
O	867	872	TUNEL
O	873	879	method
O	879	880	.

O	881	884	The
O	885	895	expression
O	896	898	of
O	899	902	Bcl
O	902	903	-
O	903	904	2
O	905	908	and
O	909	912	Bax
O	913	921	proteins
O	922	926	were
O	927	935	examined
O	936	938	by
O	939	941	SP
O	942	962	immunohistochemistry
O	962	963	.

O	964	967	The
B-outcome	968	977	apoptotic
I-outcome	978	983	index
O	984	986	of
O	987	990	the
O	991	1001	metastatic
O	1002	1008	cancer
O	1009	1014	cells
O	1015	1017	in
O	1018	1021	Epi
O	1021	1022	-
O	1022	1024	CH
O	1025	1030	group
O	1031	1034	was
O	1035	1044	increased
O	1045	1055	remarkably
O	1056	1058	in
O	1059	1069	comparison
O	1070	1074	with
O	1075	1079	that
O	1080	1082	in
O	1083	1086	the
O	1087	1094	control
O	1095	1100	group
O	1101	1102	[
O	1102	1103	(
B-iv-cont-mean	1103	1104	9
I-iv-cont-mean	1104	1105	.
I-iv-cont-mean	1105	1106	5
O	1106	1107	+
O	1107	1108	/
O	1108	1109	-
B-iv-cont-sd	1109	1110	2
I-iv-cont-sd	1110	1111	.
I-iv-cont-sd	1111	1112	7
O	1112	1113	)
O	1114	1115	%
O	1116	1118	vs
O	1119	1120	(
B-cv-cont-mean	1120	1121	3
I-cv-cont-mean	1121	1122	.
I-cv-cont-mean	1122	1123	8
O	1123	1124	+
O	1124	1125	/
O	1125	1126	-
B-cv-cont-sd	1126	1127	1
I-cv-cont-sd	1127	1128	.
I-cv-cont-sd	1128	1129	4
O	1129	1130	)
O	1131	1132	%
O	1132	1133	,
O	1134	1135	P
O	1135	1136	<
O	1136	1137	0
O	1137	1138	.
O	1138	1140	01
O	1140	1141	)
O	1141	1142	.

O	1143	1151	Compared
O	1152	1156	with
O	1157	1160	the
O	1161	1168	control
O	1169	1174	group
O	1174	1175	,
O	1176	1179	the
B-outcome	1180	1190	expression
I-outcome	1191	1193	of
I-outcome	1194	1197	Bcl
I-outcome	1197	1198	-
I-outcome	1198	1199	2
I-outcome	1200	1203	and
I-outcome	1204	1207	Bax
I-outcome	1208	1216	proteins
O	1217	1221	were
O	1222	1224	up
O	1224	1225	-
O	1225	1234	regulated
O	1235	1248	significantly
O	1249	1251	in
O	1252	1255	Epi
O	1255	1256	-
O	1256	1258	CH
O	1259	1264	group
O	1265	1266	(
O	1266	1267	P
O	1267	1268	<
O	1268	1269	0
O	1269	1270	.
O	1270	1272	05
O	1273	1276	and
O	1277	1278	P
O	1278	1279	<
O	1279	1280	0
O	1280	1281	.
O	1281	1283	01
O	1283	1284	,
O	1285	1297	respectively
O	1297	1298	)
O	1298	1299	,
O	1300	1309	resulting
O	1310	1312	in
O	1313	1322	decreased
B-outcome	1323	1328	ratio
I-outcome	1329	1331	of
I-outcome	1332	1335	Bcl
I-outcome	1335	1336	-
I-outcome	1336	1337	2
I-outcome	1337	1338	/
I-outcome	1338	1341	Bax
O	1341	1342	.

O	1343	1352	Lymphatic
O	1353	1365	chemotherapy
O	1366	1369	can
O	1370	1377	promote
O	1378	1382	cell
O	1383	1391	apotosis
O	1392	1394	in
O	1395	1403	axillary
O	1404	1414	metastasis
O	1415	1417	of
O	1418	1424	breast
O	1425	1431	cancer
O	1431	1432	,
O	1433	1438	which
O	1439	1442	may
O	1443	1449	result
O	1450	1454	from
O	1455	1464	decreased
O	1465	1470	ratio
O	1471	1473	of
O	1474	1477	Bcl
O	1477	1478	-
O	1478	1479	2
O	1479	1480	/
O	1480	1483	Bax
O	1483	1484	.
